Loading...
•
Dec 31, 2024
Gilead Sciences Q4 2024 Earnings Report
Key Takeaways
Gilead Sciences reported strong Q4 2024 results with total revenue increasing by 6% year-over-year to $7.6 billion, driven by growth in HIV, Oncology, and Liver Disease product sales. EPS increased to $1.42 from $1.14 in Q4 2023, and non-GAAP EPS rose to $1.90. Operating income grew to $2.45 billion, supported by higher product sales and lower costs. Cash and cash equivalents stood at $10.0 billion as of December 31, 2024.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Gilead expects stable revenue growth in 2025, with projected product sales between $28.2 billion and $28.6 billion. The company anticipates non-GAAP EPS in the range of $7.70 to $8.10, supported by strong HIV and Oncology demand.
Positive Outlook
- Continued strong demand for HIV and Oncology products
- Expansion in Liver Disease portfolio with new product launches
- Improved operational efficiencies driving margin growth
- Strong cash flow supporting dividend and stock repurchases
- Potential launch of lenacapavir for HIV PrEP in Summer 2025
Challenges Ahead
- Declining Veklury sales due to lower COVID-19 hospitalizations
- Higher operating expenses driven by litigation accruals and marketing costs
- Unrealized losses on equity investments impacting bottom line
- Increased R&D expenses due to new clinical trials and acquisitions
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...